Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
Saved in:
| Main Author: | Paul Y. Kwo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2024-10-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2024-0425.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
by: Seren M. Gedallovich, et al.
Published: (2024-10-01) -
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-directacting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
by: Seren M. Gedallovich, et al.
Published: (2024-10-01) -
Statin Monotherapy Not Inferior to Aspirin or Combined Aspirin and Statins Reducing the Incidences of Cirrhosis, HCC, and Mortality in MAFLD/MASH Patients: A Population Cohort Study
by: Lee CH, et al.
Published: (2024-12-01) -
Association of Statin, Metformin, and Aspirin Use With Hepatocellular Carcinoma in the All of Us Research Program
by: Erik Almazan, et al.
Published: (2025-01-01) -
Genetic polymorphism of hepatitis C virus and risk of hepatocellular carcinoma
by: S. N. Mammayev, et al.
Published: (2014-09-01)